Granted Patent B2

US 12,655,150 · App. 17/704,126 · Granted Jun 16, 2026

Inventors: Glen Robert Rennie (Somerville, MA); C. Eric Schwartz (Marblehead, MA); Louise Kirman (Swampscott, MA); Dale Porter (Cambridge, MA); Ling Song (Cambridge, MA)

Assignee: Cedilla Therapeutics, Inc.

C07D487/04C07D215/14C07D215/233C07D239/74C07D401/04C07D401/12C07D405/04C07D471/04C07D471/14C07D519/00

Abstract

Claims (15)

1 . A compound of Formula I-n-v:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is C(O)OR or N(R)C(O)R;

R 3 is OR, N(R) 2 , SR, CN, C(O)R, C(O)OR, C(O)N(R) 2 , SO 2 N(R) 2 , OC(O)R, N(R)C(O)R, N(R)SO 2 R, or an optionally substituted group selected from a 3- to 6-membered saturated or partially unsaturated carbocyclic ring, a 3- to 7-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5- to 6-membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each R is independently hydrogen or an optionally substituted group selected from C 1-6 aliphatic, a 3- to 6-membered saturated or partially unsaturated carbocyclic ring, a 4- to 6-membered saturated or partially unsaturated bridged bicyclic or spirocyclic carbocyclic ring, a saturated or partially unsaturated 3- to 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, phenyl, and a 5- to 6-membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or:

two R groups on the same nitrogen atom may, together with the atoms to which they are attached, form an optionally substituted saturated or partially unsaturated 3- to 6-membered heterocyclic ring having 0-1 additional heteroatoms selected from nitrogen, oxygen, and sulfur; and

R º is C 1-6 aliphatic or a 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R º is optionally substituted with halogen or -(haloR • ), wherein R • is C 1-4 aliphatic.

2 . The compound according to claim 1 , wherein R 1 is selected from

3 . The compound according to claim 1 , wherein R 3 is selected from OR and N(R)C(O)R.

4 . The compound according to claim 1 , wherein R is selected from the group consisting of H, CH 3 , CH 2 CH 3 , cyclopropyl,

5 . The compound according to claim 1 , wherein R 1 is C(O)OR.

6 . The compound according to claim 1 , wherein R º is —CF 3 .

7 . A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

8 . A compound selected from

or a pharmaceutically acceptable salt thereof.

Assignments (1)

Continuity (4)

References Cited (97)